27

Stapleford-Athens 2011 International Addiction Conference Further Experience with Ambulatory Benzodiazepine detox Dr George O’Neil [email protected]

Embed Size (px)

Citation preview

Stapleford-Athens 2011International Addiction Conference

Further Experience with Ambulatory Benzodiazepine detox

Dr George O’[email protected]

Fresh Start Recovery ProgrammePerth, Western Australia

History of Flumazenil treatment for benzodiazepine addiction

• 1961: Hollister, L.E., Motzenbecker, F.P. & Degan, R.O. (1961) Withdrawal reactions from chlordiazepoxide ('Librium'). Psychopharmacologia, 2, 63-68.

• 1982: McNicholas, L.F. & Martin (1982) The effect of a benzodiazepine antagonist, R015-1788, in diazepam dependent rats. Life Science. Vol 31, (8); 731-737.

• 1991: Savic, I., Widen, L, & Stone-Elander, S. (1991) Feasibility of reversing benzodiazepine tolerance with flumazenil. Lancet 337: 133-137

• 1992: Lader, M.H. & Morton S.V. (1992) A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal. Journal of Psycopharmacology 6(3);357-363.3

[email protected]

History - continued• 1996: Gerra, G. et al (1996) Intravenous flumazenil following prolonged

exposure to lormetazepam in humans: lack of precipitated withdrawal. International Clinical Psychopharmacology, Jun;11(2):81-8

– IV flumazenil following prolonged exposure to lormetazepam• 2002: Gerra, G. Zaimovic, A., Giusti, F., Moi, G. & Brewer, C (2002)

Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo-controled study. Addiction Biology, 7(4):385-95

- 50 patients 20 flumazenil. 20 oxazepam taper; 10 placebo- Demonstrated flumazenil efficiency at reversing benzo effects and withdrawal

symptoms.• 2004: Pericic, D. et al (2004) Chronic exposure of cells expressing

recombinant GABBA receptors to benzodiazepine antagonist flumazenil enhances the maximum number of benzodiazepine binding sites. Life Science, Vol 76 (3):303-317

– Prolonged occupancy of benzo receptors by benzos leads to uncoupling of the allosteric linkages to the GABBA receptor.

– Result - Tolerance/ craving for benzos, Flumazenil – recouples receptor function– Resets tone. Tolerance & cravings decrease.

[email protected]

Background• Gerra et al (2002) demonstrated that

flumazenil was efficient at reversing the effects of benzodiazepine and withdrawal symptoms.

• In 2006, we reported IV flumazenil infusions in 29 benzodiazepine dependent patients

[email protected]

Experience with flumazenil infusions• Melbourne

– 2005-2008 IV only– 2009-2011 (SC only)– 4 day (In Patient only)

• Perth– 2005-2008 IV only (usually 4 days)– 2009-2011 SC only (4-30 days)– out patient with carer after first 2 days.

[email protected]

Flumazenil 12mg/30ml filtered infusion system

[email protected]

Jon Currie, Melbourne Blood Levels

[email protected]

Perth Flumazenil Work• Continuous infusion of 100-400µg/hr causes some

detox symptoms in the first 6hrs with relief of anxiety and aggression during the infusion.

• Subcutaneous infusion have proven more reliable in more than 100 patients compared to 100 managed by IV infusion

• Patients were noted to have a return of anxiety when the infusion stoped and so the infusion is now continued up to 30 days

[email protected]

Flumazenil reducing cravings for Benzodiazepines

[email protected]

Hood, S., O’Neil, G & Hulse, G. (2009) The role of flumazenil in the treatment of benzodiazepine dependence: physiological and psychological profiles. Journal of Psychopharmacology, 23(4);401-409

Perth Flumazenil Work cont.• Perth is the first city to allow the patients

home providing a carer remains with them after the first 1-2 days of infusion.

• Research work is continuing; – Flumazenil implants– Flumazenil injections 7-28 days– Flumazenil patches

[email protected]

Prolonged infusions

• Detox symptoms in first 6 hours usually.• Detox symptoms usually settle but in high

benzo users can continue for days.• Anxiety may return when infusion stops but

the return of anxiety is decreased with long infusions.

• Anxiety control, cognitive depression and depression symptoms all improve with length of the infusion.

[email protected]

In Vitro Release of FLU/PLA/PLGA tablets

[email protected]

Perth Flumazenil Infusions Aug 2010

• 100+ IV infusions balloon driven– Patients became irritable whenever the

infusion was stop by a blocked IV site– On one occasion a patient fitted

• 100+ Subcutaneous infusions– No obstructions to flow occurred and

outpatient management became practical

[email protected]

Drug use Before & After Naltrexone & Flumazenil (Hood, 2009)

[email protected]

Flumazenil Reducing Anxiety (Hood, 2009)

[email protected]

Flumazenil infusions the future

• Subcutaneous has replaced IV• Nasal may be useful for symptom control.• Transdermal experiments are continuing.• Implant delivery; trial protocols are

developed.• Use in benzo addiction is well demonstrated.• Use in alcohol, amphetamine and other

addictions is less well established.

[email protected]

Karolinska Institute 2010• In aggressive patients flumazenil

decreases the existing aggression

• In the control group, flumazenil increases aggression and alertness

• The dose delivery method of large bolus intermittent doses may have caused aggression in the controls where it is my belief that a continuous low dose infusion might have increased alertness without increasing aggression.

[email protected]

Saxon, L., Borg, S. & Hiltunen, A.J. (2010) Reduction of aggression during benzodiazepine withdrawal: Effects of flumazenil. Pharmacology, Biochemistry and Behaviour, 96, 148-151

Croatia 2008, Molecular & Neuropharmacology

• They confirm up-regulation of GABAA receptors may be from;

– Growth of new receptors via synthesis of receptor proteins confirmed with their experiments during prolonged flumazenil exposure

or– Via flumazenil causing the correction of uncoupling of

non sensitive GABAA receptors so that they return to full sensitivity

(uncoupling of receptors follows exposure to benzodiazepines)

Jazvinscak, M. et al (2008) The role of transcriptional and translational mechanisms in flumazenil-induced up-regulation of recombinant GABAA receptors. Neuroscience Research, 61;234-241

[email protected]

GABAA Receptor

[email protected]

Case Study – Female Aged 30

• Childhood terror• PTSD diagnosed at 15• Anxiety led to 20 years benzo and 10 years

opiate addiction• Total of 35 admissions for benzo overdoses

requiring ventilation occurred

[email protected]

Case Study – Female Aged 30 cont.• Presenting medications:

– 200 x 2mg/day Xanax (alprazolam)– 50 x 5mg/day Valium (diazepam)– 50 x 5mg/day Mogadon (nitrazepam)– 1600 mg/day Seroquel (quetiapine: atypical antipsychotic)– 80/day Panadeine Forte (co-codamol: each tablet paracetamol 500 mg

+ codeine phosphate 30 mg)

• Naltrexone implants to control the opiate disorder• Flumazenil infusions to control the GABAA system

anxiety disorder

[email protected]

Heart rate patterns following Valium at midday and flumazenil at 6.15pm

He

art

ra

te (

bp

m)

Valium (agonist) Flumazenil (antagonist)1

20

0

16

00

20

00

40

60

80

100

120

140

[email protected]

Case Study – female aged 50

• PTSD following presence at 9/11• Stilnox addiction (agonist at benzo receptor)

followed sleep disturbance• Culminating in 20 tab/day Stilnox (zolpidem)• Treated with flumazenil infusions to

upregulate (re-sensitise) the benzo receptors damaged by chronic stress from PTSD and Stilnox

[email protected]

Contact Information• Dr George O’Neil• Email: [email protected]• Phone +61 893881991

– Perth (GMT+8) 6-8am or 7-11pm– London (GMT) 10-12pm or 11am-3pm– New York (GMT-5) 5-7pm or 6-10am– Los Angeles (GMT-8) 2-4pm

[email protected]